However, toxicity was greatly improved by weekly dosing, with a significant reduction in fever, hepatotoxicity and veno-occlusive disease.89 A second phase 2 study of 35 patients with CD22+ ALL in second salvage or later showed similar complete response rate (66%) and median overall survival (7.4 months).90 Based on these results, Kantarjian et al.91 compared weekly dosing of InO to standard chemotherapy for relapsed/refractory ALL. This evidence concerns the gene CD22 and hepatic veno-occlusive disease.